

THE ROLE OF ANTI-VEGF IN MANAGEMENT OF PTERYGIUM

Essay

*Submitted for Partial Fulfillment of Master Degree
in Ophthalmology*

By

Dina Adel Ghazy
M.B.B.Ch.

Supervised by

Prof. Dr. Magda Mohammed Mahmoud Samy

*Professor of Ophthalmology
Faculty of Medicine- Ain Shams University*

Dr. Sameh Hany Abd El Rahman

*Lecturer of Ophthalmology
Faculty of Medicine- Ain Shams University*

***Faculty of Medicine
Ain Shams University
Cairo-2012***

Acknowledgement

I would like to express my profound gratitude to Prof. Dr. Magda Mohammed Mahmoud Samy, for her patience, valuable inspiration, guidance and motivation. Her constructive encouragement and great help were behind the accomplishment of this work.

I am greatly indebted to Dr. Sameh Hany Abd El Rahman, for dedicating his time and effort to the supervision of this study, providing me with valuable remarks and generous advice.

Finally, I feel thankful to my parents for their help and support.

Contents

	<i>Page</i>
*List of figures	I
*List of tables	III
*List of abbreviations	IV
*Introduction	1
*Aim of the study	2
*Chapter 1: Anatomy of the ocular surface.....	3
➤ Anatomy of the cornea	3
➤ Anatomy of the conjunctiva	10
➤ Anatomy of the limbus	14
*Chapter 2: Physiology of the cornea.....	16
➤ Corneal metabolism	16
➤ Control of corneal hydration	17
➤ Corneal wound healing	19
*Chapter 3: Pathogenesis of pterygium	21
➤ Epidemiology	21
➤ Clinical Manifestations	21
➤ Histopathological Features	23
➤ Pathogenetic Theories	24

*Chapter 4: Different modalities used in the management of pterygium	30
➤ Surgical techniques used in the management of pterygium.....	32
➤ Adjunctive therapy.....	36
*Chapter 5: The role of anti-VEGF drugs in the management of pterygium	39
➤ Vascular endothelial growth factor	39
➤ Anti-VEGF drugs	40
➤ The role of subconjunctival injection of anti-VEGF drugs	43
➤ The role of intralesional Bevacizumab	53
➤ The role of topical Bevacizumab	55
➤ Anti-VEGF drugs and wound healing	57
*Summary	60
*References	62
*Arabic summary	—

List of Figures

<i>Figure No.</i>	<i>Page</i>
Figure 1: Microscopic anatomy of the Cornea	3
Figure 2: Cross sectional view of corneal epithelial layer	5
Figure 3: Organization of keratocytes in corneal stroma showing interconnections across lamellae	8
Figure 4: Corneal endothelium and Descemet's membrane	8
Figure 5: Gross Anatomy of the conjunctiva	10
Figure 6: Conjunctival histology	11
Figure 7: Factors and forces involved in the control of corneal stroma hydration	17
Figure 8: Clinical presentation of Pterygium	22
Figure 9: Histopathological appearance of pterygium ..	23
Figure 10: Pterygium encroaching on visual axis	31
Figure 11: Inflamed pterygium	31
Figure 12: External photograph of an eye after intraoperative mitomycin therapy showing corneo-scleral necrosis and early infection ...	38

Figure 13: External photographs of appearance of the same eye, 1month (<i>left</i>), and 6 months (<i>right</i>) after postoperative mitomycin application showing scleritis, followed by scleral thinning	38
Figure 14: Inflamed pterygial bed after excision of a large pterygium	45
Figure 15: The same case one week after subconjunctival Bevacizumab (0.1ml or 2.5mg)	45
Figure 16: Slit lamp photographs of patients before and after injection of Bevacizumab	48
Figure 17: Slit lamp photographs of the surgical bed 1 week after surgery in contemporary control patients versus study patients demonstrating decreased vascularity of conjunctival autograft	51
Figure 18: Slit lamp photographs demonstrating preoperative and postoperative pterygium appearance in 5 patients whose conjunctival autografts were fixated with sutures	52
Figure 19: Photographs demonstrating preoperative and postoperative pterygium bed appearance in a patient whose conjunctival autograft was fixated with fibrin glue, demonstrating graft dehiscence and underlying bare sclera	58

List of Tables

<i>Table No.</i>	<i>Page</i>
Table 1: Summary of clinical trials conducted to assess the effect of subconjunctival Bevacizumab on pterygium size	46
Table 2: Summary of clinical trials conducted to assess the effect of subconjunctival Bevacizumab on pterygium size	49
Table 3: Summary of clinical trials Conducted to assess the effect of intrlesional Bevacizumab on primary and recurrent pterygium	54
Table 4: Summary of clinical trials conducted to study the effect of topical Bevacizumab on impending recurrent pterygium	56

List of Abbreviations

AMP:	Adenosine monophosphate
ARMD:	Age related macular degeneration
ATP:	Adenosine triphosphate
CAG:	Conjunctival autograft
CLAG:	Conjunctival limbal autograft
DNA:	Deoxyribonucleic acid
FDA:	Food and drug administration
FGF-2:	Fibroblast growth factor- 2
GAC:	Glycosaminoglycan
HMP:	Hexose monophosphate
HPV:	Human papiloma virus
IL:	Interleukin
MMC:	Mitomycin C
MMPs:	Matrix metalloproteinases
PDGF:	platelet derived growth factor
RNA:	Ribonucleic acid
TCA:	Tricarboxylic acid
TGF- :	Transforming growth factor beta
TNF-a:	Tumor necrosis factor alpha
TSP-1:	Thrombospondin-1
USA:	United States of America
UVR:	Ultraviolet radiation
VEGF:	Vascular endothelial growth factor

Introduction

A pterygium is an elevated, superficial, external ocular lesion that is formed over the perilimbal conjunctiva and extends onto the corneal surface.¹ It is a common disorder of the ocular surface, with a prevalence of 2% in temperate areas and up to 20% in tropical regions.²

The pathogenesis behind its formation is not fully understood. Various studies have implicated environmental factors, such as ultraviolet light, chronic irritation, and inflammation. Recent studies have also provided evidence implicating genetic components, antiapoptotic mechanisms, cytokines, growth factors, extracellular matrix remodeling, immunological mechanisms, and viral infections in the pathogenesis of the disease.³

Immunohistochemistry studies show that immunostaining of VEGF is more intensive in pterygial sections than in normal conjunctival sections. Decreased angiogenic inhibitors, together increased stimulators, have been hypothesized as playing roles in the formation and progression of pterygia.⁴

Surgical excision of pterygium is generally essential when the visual axis is threatened and/or the pterygium causes severe irritation or cosmetic problems.⁵

The primary aim is to excise the pterygium and prevent its recurrence. As bare sclera excision is associated with a high recurrence rate, pterygium excision is often combined with conjunctival autograft, mitomycin C, beta-irradiation, or other adjunctive therapies to reduce recurrence rates.⁶

Anti-VEGF treatment has shown great promise in other ocular neovascular diseases and potentially has a significant role in inhibiting fibroblastic and neovascular proliferation that promotes pterygium growth and recurrence.⁷

Aim of the Study

The aim of this study is to highlight the role of anti-VEGF drugs in the management of pterygium.

Anatomy Of The Cornea

Gross Anatomy:

A healthy cornea, together with the overlying tear film, is necessary to provide a proper anterior refractive surface and to protect the eye against infection and structural damage. In the adult, the average horizontal diameter is 11.5-12 mm and about 1.0 mm larger than the vertical diameter. The shape of the cornea is prolate, being flatter in the periphery and steeper centrally, which creates an aspheric optical system.⁸

Microscopic Anatomy

The cornea consists of five layers, the epithelium, Bowman's layer, the substantia propria, Descemet's membrane and the endothelium.⁹ (Fig.1)




Fig. 1: Microscopic Anatomy of the cornea.⁸

Epithelium: It is composed of nonkeratinized, nonsecretory stratified squamous epithelium.⁸

It is typically several cell layers thick, consisting of the apical squamous cell layer, the multilayered, polygonal-shaped wing cells beneath the apical layer, and the posterior-most layer basal cells (Fig.2).

Apical surface cells appear broad and flattened, freshly emerged surface cells appear bright during specular microscopy and have relatively small numbers of microvilli covering their apical membrane. The margins of the apical cell membrane possess the important tight junctions surrounding the cell circumference near the apical margin. The lateral and basal membranes of the apical cells have gap junctions, numerous desmosomal junctions, and numerous membrane-bound vesicles.

Wing cells are distinguished by a variety of polygonal shapes and by their large ovoid nuclei. The cells are roughly 12 to 15µm in diameter, and their cytoplasm contains few rough endoplasmic reticulum, mitochondria, or Golgi's complexes.¹⁰

Basal cells appear as elongated polygonal cells approximately 10µm in width and 15 to 20µm in height, with prominent ovoid nuclei.¹¹ They possess lateral intercellular junctions characterized by being gap junctions and zonulae

adherens,⁸ the basal membrane is notable for the presence of hemidesmosomes.¹⁰




Fig. 2: Cross-sectional view of the corneal epithelial cell layer.⁸

Bowman's Layer: Bowman's layer lies immediately beneath the basement membrane of the corneal epithelium. It measures about 8 to 12 μm in thickness. It is acellular and consists of interwoven collagen fibrils embedded in intercellular substances. Electron microscopy reveals its collagen to be finer and more randomly arranged than that in the substantia propria. Bowman's membrane ends abruptly at the limbus. Its deep surface merges into the substantia propria.⁹

Stroma: The stroma is composed predominantly of type I collagen with types III, V, and VI also in evidence.¹⁰

It is estimated that there are about 200 to 250 flattened lamellae, each of which is 2 μm thick. The direction of the collagen fibrils in any given lamella is the same, but they run at right angles to those of adjacent lamellae. The collagen fibrils measure between 21 and 65 nm in diameter.⁹

After collagen, proteoglycans are the second most abundant biological constituents of the cornea, constituting approximately 10% of the dry weight of the cornea. Proteoglycans are glycosylated proteins with at least 1 glycosaminoglycan (GAG) chain bound to the protein core. GAGs are composed of repeating disaccharides. The GAGs found in corneal stroma include Keratan sulfate, Chondroitin sulfate and Dermatan sulfate.

Matrix metalloproteinases (MMPs), a family of Zn^{2+} - dependent enzymes, are responsible for degradation of the components of the extracellular matrix (including proteoglycans and various types of collagen) during normal development as well as in disease processes. Of more than a dozen known metalloproteinases, only MMP2 proenzyme has been found in the healthy cornea.¹²

Keratocytes: The lamellar stroma is secreted and maintained by the stromal fibroblasts, commonly termed

Keratocytes. Keratocytes are flat, with many long attenuated processes, extending from a central cell body in all directions, the tips of the processes touch processes of adjacent cells forming gap junctions (Fig.3). Thus, cells of the stroma form a network of coupled cells. The cytoplasm of the stromal fibroblast is rich in rough endoplasmic reticulum and golgi apparatus, in keeping with its function as the synthesizer and maintenance cell of the stromal lamellae. Recent data suggest that the stroma also houses a relatively high number of bone marrow derived cells.¹³

Descemet's membrane: Descemet's membrane is a 10- μ m-thick specialized basement membrane present between the endothelium and posterior stroma. It is secreted by endothelium and is constituted of an anterior banded portion and a posterior nonbanded portion (Fig.4). Type IV collagen is the most abundant collagen in Descemet's membrane.¹²

Endothelium: The human corneal endothelium is a single layer of 400,000 to 500,000 cells. Cells are 4 to 6 μ m in height and 20 μ m in width, and their posterior surfaces are predominantly hexagonal when viewed under specular microscopy.¹⁰

A group of tight junctions forms the junctional complex that occludes the lateral extracellular spaces from the aqueous humor.¹²